|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
Valuation Estimation |
EPS (Current/Estimated)
-2.48/-2.80
|
Enterprise Value
267.87M
|
Balance Sheet |
Book Value Per Share
8.28
|
Cash Flow |
Cash Flow Yield
--
|
Income Statement |
Total Revenue
33.49M
|
Operating Revenue Per Share
--
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Quotes are at least 15-min delayed:2024/12/24 13:20 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
|
|||
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program ofthe company includes Artiva-Funded Trials and Collaborator-Funded Trials. |